Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Projects Nine NME Filings By 2010, Keeping Pace With Previous Years

Executive Summary

With the Jan. 22 filing of the pain medication tapentadol, Johnson & Johnson made the first of the nine new molecular entity filings it expects to make through 2010

You may also be interested in...



J&J’s Tapentadol Raises Competitive Bar in Pain Market

Johnson & Johnson's newly approved acute pain drug tapentadol will likely face more market competition from tramadol generics than the drug the company compared it to in Phase III studies - oxycodone, analysts say

J&J’s Tapentadol Raises Competitive Bar in Pain Market

Johnson & Johnson's newly approved acute pain drug tapentadol will likely face more market competition from tramadol generics than the drug the company compared it to in Phase III studies - oxycodone, analysts say

J&J’s Dapoxetine Has Sound Safety Profile, But Will FDA Be Satisfied?

Johnson & Johnson's investigative short acting selective serotonin reuptake inhibitor dapoxetine produced no reports of suicidality in Phase III trials for premature ejaculation

Related Content

UsernamePublicRestriction

Register

PS049263

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel